Dr. Duncavage is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1 Barnes Jewish Hospital Plz
# Div
Saint Louis, MO 63110Phone+1 314-362-5641Fax+1 314-362-0369
Education & Training
- University of Utah HealthFellowship, Hematopathology, 2009 - 2010
- Washington University/B-JH/SLCH ConsortiumFellowship, Molecular Genetic Pathology, 2008 - 2009
- Washington University/B-JH/SLCH ConsortiumResidency, Pathology-Anatomic and Clinical, 2004 - 2008
- University of Tennessee Health Science Center College of MedicineClass of 2004
Certifications & Licensure
- IL State Medical License 2014 - 2026
- MO State Medical License 2007 - 2026
- UT State Medical License 2009 - 2012
- American Board of Pathology Pathology - Anatomic/Pathology - Clinical
- American Board of Pathology Clinical Informatics
- American Board of Pathology Pathology - Molecular Genetic
- American Board of Pathology Hematopathology
Publications & Presentations
PubMed
- Clinical-genomic profiling of MDS to inform allo-HSCT:Recommendations from an international panel on behalf of the EBMT.Carmelo Gurnari, Marie Robin, Lionel Adès, Mahmoud Aljurf, Antonio M Almeida
Blood. 2025-02-19 - A fully next-generation sequencing-based method of classifying molecular sub-types of endometrial cancer retains prognostic value and expands biomarker targets.Mark C Valentine, Amanda Wong, Ling Chen, Feiyu Du, Andrew E O Hughes
International Journal of Gynecological Cancer. 2025-02-01 - Analytical performance of OncoPrism-HNSCC, an RNA-based assay to inform immune checkpoint inhibitor treatment decisions for recurrent/metastatic head and neck squamous...Jeffrey Hiken, Jon Earls, Kevin C Flanagan, Rachel L Wellinghoff, Michelle Ponder
BMC Cancer. 2025-01-07
Journal Articles
- TP53 Immunohistochemistry Correlates TP53 Mutation Status and Clearance in Decitabine-Treated Patients with Myeloid MalignanciesJohn S Welch, Eric J Duncavage, Haematologica
- Exome Analysis of Treatment‐Related AML After APL Suggests Secondary EvolutionJohn S Welch, Eric J Duncavage, Meagan A Jacoby, Peter Westervelt, Lukas D Wartman, British Journal of Haematology
- Discriminating a Common Somatic ASXL1 Mutation (c.1934dup; p.G646Wfs*12) from Artifact in Myeloid Malignancies Using NGSJonathan W Heusel, Richard D Press, Matthew J Walter, Eric J Duncavage, Nature
Press Mentions
- Birthplace of Precision MedicineNovember 14th, 2024
- Cofactor Genomics Publishes Clinical Validation of OncoPrism-HNSCC, a Test Leveraging Novel RNA Modeling Technology to Predict Response to ImmunotherapyNovember 7th, 2024
- As Use of Large Cancer Panels and Whole-Genome Sequencing Expands, Illumina Plans to Future-Proof NGS Interpretation and ReportingMarch 28th, 2023
- Join now to see all
Grant Support
- A Rapid and Comprehensive Approach for Clinical Genomic Profiling in Lung CancerWASHINGTON UNIVERSITY2023–2026
- A Rapid and Comprehensive Approach for Clinical Genomic Profiling in Lung CancerWASHINGTON UNIVERSITY2023–2026
- A Rapid and Comprehensive Approach for Clinical Genomic Profiling in Lung CancerWASHINGTON UNIVERSITY2023–2026
- Genome sequencing for evaluating the efficacy, specificity, and safety of human genome editingWASHINGTON UNIVERSITY2023–2026
- Whole Genome Sequencing for Genomic Evaluation and Risk Stratification of Patients with Myelodysplastic SyndromesWASHINGTON UNIVERSITY2022–2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: